In the second quarter it paid to be a leading obesity company. As for Covid, not so much.
J&J moves FcRn towards a big new therapy area, while Bristol, Merck, Astrazeneca and Daiichi Sankyo await important oncology catalysts.
The company’s stock surges 236% on first data with its new EGFR project, so where’s the catch?
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
After a hiatus Nkarta comes back with a new lymphodepletion regimen to boost its lead Car-NK therapy.